Hormone Therapy Safety in Menopause: What 2026 Reviews Reveal

Two reviews published in 2026 arrive at a shared conclusion: hormone therapy’s long-term safety depends less on the hormones themselves than on who takes them, how they are delivered, and when treatment begins. For women weighing menopausal hormone therapy (MHT), the evidence is more reassuring — and more specific — than most headlines suggest.

Exogenous Hormones Quiet the Body’s Signaling — Unless It Is Already Silent

Cretu and colleagues at the Grigore T. Popa University of Medicine and Pharmacy in Iași, Romania, describe in Frontiers in Reproductive Health what happens when men take testosterone replacement therapy for extended periods. The hypothalamic-pituitary-testicular (HPT) axis reads the external testosterone as a plentiful supply and dials down its own output. Gonadotropin production falls, intratesticular testosterone drops, sperm production stalls, and the testicles can atrophy. Current recovery tools — human chorionic gonadotropin (hCG), follicle-stimulating hormone (FSH), and selective estrogen receptor modulators (SERMs) — work inconsistently, and the authors identify kisspeptin, gonadotropin-releasing hormone (GnRH) approaches, and neurokinin signaling as experimental options. They are careful to note that direct proof of restored fertility after TRT-induced suppression remains thin.

Here is why this matters for women. Negative feedback matters only when there is a functioning axis to suppress. After menopause, the ovaries are already quiescent; MHT replaces hormones the body no longer produces rather than switching off active production. That distinction explains why MHT safety debates center on breast, endometrial, and cardiovascular outcomes — not on fertility or glandular “shutdown,” as some popular claims suggest.

HRT After Gynecologic Cancer: A Wide Gap Between Evidence and Practice

A second 2026 review, by Gil-Ibáñez and co-authors published in the International Journal of Gynecological Cancer, examines hormone replacement therapy in women who have survived gynecologic cancers. Their central finding: clinical practice lags well behind the evidence. Many survivors are denied HRT out of caution, yet the accumulated data support its use after most endometrial, ovarian, and cervical cancers, with symptom relief and quality-of-life benefits and no convincing signal of harm for the majority of these patients. Breast cancer remains the more contested case, requiring individualized decisions.

What This Means for Long-Term Safety

Decades of trial data, including the Women’s Health Initiative, support what researchers call the timing hypothesis: starting MHT before age 60 or within about 10 years of the final menstrual period yields a favorable benefit-risk balance, while starting later shifts the calculus toward risk. Route also matters. Oral estrogen passes through the liver first, raising clot-related proteins and roughly doubling venous thromboembolism risk; transdermal patches and gels largely avoid this first-pass effect, a reason transdermal estrogen has become the preferred delivery route.

Progestogen deserves equal attention. Women with an intact uterus must take progestogen alongside estrogen to prevent endometrial hyperplasia and cancer — this is one of the clearest, longest-standing findings in the field. Breast risk splits by regimen: combined estrogen-progestin therapy shows a small increase after roughly 3–5 years of use, on the order of a few extra cases per 10,000 women per year, while estrogen-only therapy did not raise breast cancer incidence in trial data. For women who enter menopause suddenly after hysterectomy, surgical menopause carries its own cardiovascular considerations that strengthen the case for estrogen.

Practical Applications

• Timing is the strongest safety lever. If MHT is appropriate, starting within 10 years of menopause or before 60 offers the most favorable long-term profile.
• Ask about transdermal options if you have clot risk factors, migraine with aura, or elevated triglycerides.
• Never take estrogen alone with an intact uterus; progestogen protection is non-negotiable for endometrial safety.
• Consider low-dose vaginal estrogen for genitourinary symptoms — systemic absorption is minimal and it can be used long term.
• Cancer survivors should ask directly whether HRT is an option; the 2026 review suggests many are refused unnecessarily.
• Re-evaluate annually. Duration should be individualized, not dictated by an arbitrary cutoff.

Both 2026 reviews converge on the same message: blanket fear of hormone therapy is not supported by the evidence. Context — age, route, regimen, and personal history — determines safety far more than the hormones themselves.

Frequently Asked Questions

Does long-term MHT increase breast cancer risk?

Combined estrogen-progestin therapy shows a small increase after roughly 3–5 years of use, but estrogen-only therapy has not been shown to raise breast cancer incidence in major trial data.

Will taking estrogen shut down my own hormone production, like testosterone therapy does in men?

No. After menopause the ovarian-pituitary signaling axis is already quiet, so MHT replaces what the body no longer produces rather than suppressing an active system.

Can gynecologic cancer survivors take hormone therapy?

For most endometrial, ovarian, and cervical cancer survivors, evidence supports HRT use, though a 2026 review found many clinicians still avoid prescribing it; breast cancer requires more individualized discussion.

Is there a maximum safe duration for MHT?

No fixed limit applies to everyone; guidelines now favor individualized, ongoing benefit-risk reassessment rather than routine discontinuation at an arbitrary time point.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42666625/
https://pubmed.ncbi.nlm.nih.gov/42660774/
https://pubmed.ncbi.nlm.nih.gov/42508869/
https://pubmed.ncbi.nlm.nih.gov/42508868/
https://pubmed.ncbi.nlm.nih.gov/42506387/